● pepmg Research Desk · Peer-reviewed evidence review
What the research says about MOTS-c
A neutral summary of the peer-reviewed literature on MOTS-c, a mitochondrial-derived peptide studied almost entirely in cell and animal models of metabolism and aging. No controlled human trials exist. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- MOTS-c is a mitochondrial-derived peptide studied almost entirely in cell and animal models of metabolism, muscle, and aging [1][8].
- In mice and cell systems it activated the metabolic sensor AMPK and improved measures of insulin sensitivity, and MOTS-c levels in blood decline with age in the studies reported [1][5].
- There are no controlled human trials of MOTS-c; its human safety and efficacy are not established [4][8].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What MOTS-c is
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is described in the literature as a small peptide encoded within the mitochondrial genome that acts as a signaling molecule regulating cellular metabolism [1]. It belongs to a family of mitochondria-derived peptides that also includes humanin [8]. MOTS-c is sold by third-party research-chemical vendors and is offered for laboratory and research use only.
Essentially all of the published research on MOTS-c is preclinical, carried out in cultured cells and in animals rather than in controlled human trials [1][4].
What the preclinical research has measured
Preclinical onlyIn its founding characterization, MOTS-c was identified as a peptide encoded in the mitochondrial 12S rRNA that targets skeletal muscle and, by inhibiting a step of the folate cycle, activates the energy sensor AMPK; in that work MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice [1]. Later studies reported that MOTS-c can translocate to the cell nucleus under metabolic stress and influence stress-adaptive gene expression [7], and that it directly binds and activates the enzyme CK2 in cell-free and animal systems, with tissue-specific effects on muscle and fat [2].
Additional animal and cell work has examined MOTS-c in muscle and metabolic disease: reducing myostatin and muscle-atrophy signaling in mice and myotubes [3], and relieving hyperglycemia and insulin resistance in a mouse model of gestational diabetes [4]. Reviews summarize a plasma pool of MOTS-c that declines with age and a body of preclinical interest in metabolism, muscle, aging, and cardiovascular biology [5][6][8].
What the trials report on safety and adverse events
Preclinical onlyThere is no controlled human-trial safety data for MOTS-c to report. The peer-reviewed literature is confined to cell and animal experiments, which are not designed to establish human safety, tolerability, or adverse-event rates [1][4][8].
Reviews of MOTS-c note that, despite promising preclinical biology, it has been used little in disease treatment and that no established method exists for applying it in the clinic [5]. Because human safety is not established, nothing here should be read as evidence that MOTS-c is safe for people. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
Because the MOTS-c evidence base is entirely preclinical (cell and animal models, with no controlled human trials), it is characterized as preclinical only [1][8]. Preclinical findings, however mechanistically interesting, do not establish that a compound works or is safe in humans, and animal results frequently fail to translate.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
- MOTS-c modulates skeletal muscle function by directly binding and activating CK2.
- MOTS-c reduces myostatin and muscle atrophy signaling.
- The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus.
- MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation.
- MOTS-c functionally prevents metabolic disorders.
- MOTS-c: a mitochondrial-encoded regulator of the nucleus.
- Mitochondria-derived peptides in aging and healthspan.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.